Maxwell Biosciences
Biotech
Austin, Texas

Overall Rank: 83
Category: Biotechnology
Category Rank: 40

Profile

Founded in 2016, Maxwell Biosciences is a pre-clinical drug platform company that develops biomimetic therapeutics – synthetic compounds that mimic and improve upon natural immune system peptides. Inspired by nature, these small molecules have been shown to be effective against Ebola, pan-coronavirus, pan-Influenza A (avian flu, swine flu, and human flu), as well as all tested bacteria, fungi and biofilms – while safely avoiding healthy cells. 


Maxwell’s team is deeply committed to its vision: to create health for the world, safely and affordably. Ahead of planned FDA clinical trials in 2025, Maxwell’s compounds have been shown to be well-tolerated in human tissues in vitro, and in multiple animal studies, are shelf-stable and do not require a cold-chain. 


Maxwell has executed a co-development deal with the US Army, benefited from $27M in governmental-sponsored research, and enjoys strong support from strategic investors. Led by CEO J. Scotch McClure, who brings extensive leadership experience and strategic vision to the company, the team is dedicated to providing solutions for the world’s most intractable infectious disease problems. 


Maxwell’s technology is protected by numerous patents and is led by a world-class team who have brought dozens of drugs to market, including Adderall XR, Claritin, Carbatrol, and Equetro. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com


Key Products

Maxwell’s First-in-Class CLAROMER® brand drug-discovery platform produces small molecules that mimic the pathogen-agnostic core peptide of the innate immune system – Human Cathelicidin Antimicrobial Peptide. 


Lead Drug Candidate for Chronic Sinusitis: Maxwell’s lead drug candidate is an extremely broad spectrum anti-infective, effective against all tested pathogens associated with chronic rhinosinusitis. It also has the potential to disrupt the biofilms associated with Long COVID, infectious dementia, and other chronic, unmet medical needs associated with post viral syndromes and brain fungal infections.


According to the CDC, chronic sinusitis is suffered by around 12% of the population, causes upwards of $15B in economic costs each year, and 28,000 deaths per year in the US alone. Chronic sinusitis is often caused by combinations of fungal and bacterial infections; and there are currently no approved drugs to effectively cure this kind of infection. It is antibiotic resistant. Current treatments for chronic sinusitis are only anti-inflammatory.


Preclinical studies have established the in vitro efficacy of Maxwell’s lead drug candidate against all sinusitis-related pathogens tested to date.  Since sinusitis is potentially lethal for immunocompromised patients, the development pathway can take advantage of prioritized FDA human trials that serve to escalate solutions for lethal and completely unmet medical needs.


Universal Antimicrobial / Universal Antiviral: Several of Maxwell’s platform compounds have activity against 70+ resistant bacteria and all tested fungi. Others are extremely broad spectrum antivirals against all tested strains of Ebola, influenza, and coronaviruses (including MERS, SARS-1, SARS-CoV-2), and some other viruses of future pandemic concern.


Statistics


  • Executed US Army drug development contract

  • Planned exit 2026; 10x+ return target

  • $6B annual revenue opportunity for 1st therapeutic indication

  • Leadership team: collectively brought dozens of drugs to market worth many $ billions

  • Over $27M in gov’t sponsored research and strong support from investors

  • Positive FDA interactions

  • Total addressable market: $121B


Key Executives

Scotch McClure


Scotch is an engineer with over 20 years of experience as a CEO, and 10 years of experience as a board director. He is a multi-patent inventor including antiviral applications of Maxwell’s platform, and human gene expression technology. His background includes leading engineering and scientific research teams, as well as military intelligence and commercial applications such as high tech hardware and software.  He designed and commercialized the world’s first dual core laptop in partnership with Advanced Micro Devices. He is a pioneer in the field of plasma proteomics, Big Data computation, and biomimetic drug design. He has a wide ranging interest in physics, theory of mind and consciousness, information theory, nanobiology, and reversing aging by restoring rejuvenative homeostasis.


Ed Rudnic


Dr. Rudnic (Ed) brings more than 30 years of diverse experience in biosciences and drug discovery. He is the former head of US R&D for Shire Pharmaceuticals where he led projects that drove over $30 billion in revenue for Shire. He has successfully raised over $500M in capital at various organizations and has successfully taken a biopharma company public on the NASDAQ.  He has also been either the lead inventor or a co-inventor of 56 issued U.S. patents and numerous related international patents.


Lucas Wenthe


Lucas is a dynamic company executive, blending expansive legal acumen with deep insights into  diverse industries like synthetic biology and healthcare.  His expertise spans the spectrum from IP strategy and patent management to mergers, acquisitions, and capital ventures. With a track record of fostering international biotech and healthcare collaborations, Lucas has also adeptly procured and licensed groundbreaking patents in medical device technologies.


Tony Verco 


Tony is an anesthesiologist with over 23 years experience in the Pharmaceutical industry. He has worked in both the contract clinical research sector as well as small and large pharmaceutical companies, with experience spanning research in toxicology, pharmacology, drug safety, regulatory, commercial, and product development strategy. He has consulted to industry and managed the operational development of lead candidates from Phase 1 through Phase 3, including international phase 3 trials, in multiple therapeutic areas which included interactions with both the FDA, EMEA, and Health Canada.


Organizational Insights

Maxwell, an innovative biotechnology startup, has garnered significant attention within the biotech industry, governments around the world, and large pharmaceutical companies. With its novel drug development platform – powered by AI insight – Maxwell is committed to creating health for the world, safely and affordably.


Board Members

Joshua “Scotch” McClure, MBA, Founder, CEO & Chairman of the Board


Mr. McClure is an engineer with over 20 years of experience as a CEO, and 10 years of experience as a board director. He is a multi-patent inventor including antiviral applications of Maxwell’s platform, and human gene expression technology. His background includes leading engineering and scientific research teams, as well as military intelligence and commercial applications such as high tech hardware and software.  He designed and commercialized the world’s first dual core laptop in partnership with Advanced Micro Devices. He is a pioneer in the field of plasma proteomics Big Data computation, and biomimetic drug design. He has a wide ranging interest in physics, theory of mind and consciousness, information theory, nanobiology, and reversing aging by restoring rejuvenative homeostasis.


Major General (Ret.) Barbara Holcomb, RN, BSN, MSN


Gen Holcomb is a retired US Army Major General. Her last assignment in 2020 was Commanding General, US Army Medical Research and Materiel Command, and Fort Detrick, and Chief of the US Army Nurse Corps. She was commander of all of the Department of Defense biodefense efforts, is one of the world’s top national security biodefense research leaders, and emergency medicine practitioner leaders. She continues to volunteer as a Registered Nurse. She brings over 33 years of experience of battlefield hospital patient care and biodefense leadership. She leads Maxwell’s partnership efforts with US Department of Defense agencies, DARPA (Defense Advanced Research Projects Agency), and BARDA (the Biomedical Advanced Research and Development Authority) as the company steps forward into leading biodefense for the US, our allies and our civilization against naturally occurring, deliberate, and accidental biological threats.


Kate McKinley, MBA


Ms. McKinley has over 20 years of experience in leading strategic partnerships in the biopharmaceutical industry, positioning organizations for commercial success. Ms. McKinley currently serves as Chief Business Officer of Rani Therapeutics, a clinical stage oral drug delivery platform company. She is the former Chief Executive Officer (CEO) of Elevar Therapeutics, where she played a pivotal role in fundraising and the M&A activities that led to Elevar’s acquisition by HLB, Inc. She built and led Elevar’s global commercial, medical affairs, business development, manufacturing, supply chain, alliance management, and corporate communications organizations. Prior to joining Elevar, she was the Head of Marketing, Training, and the Hospital Channel at Dendreon, responsible for the first FDA approved cell-based cancer immunotherapy. Prior to Dendreon, Ms. McKinley was U.S. Head of Sales at AbbVie, overseeing new product launch planning, and market expansion strategies.


Investors


  • Longevity Tech.Fund

  • Keirestu Forum

  • Decentranet

  • Accelerator Venture Partners

  • David Shaw, former Venrock partner

  • Thomas Boone Pickens III

  • Alex W. Dreyfoos Jr. Trust


Key Milestones


News and Press Releases

Nov 2023: Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study (Read).


Oct 2023: Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens (Read).


Oct 2023: Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors (Read).


Aug 2023: Maxwell Biosciences Announces Publication of Mechanism of Action Study: Claromer Compounds Target Pathogens by Disrupting Their Membranes (Read).


March 2023: Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round (Read).


Feb 2023: New Research Published in ACS Infectious Diseases Examines Impact of Self-Assembly of Antimicrobial Peptoids on ESKAPE Bacterial Pathogens (Read).


May 2023: Maxwell Biosciences Announces the CLAROMER® Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials (Read).


April 2023: David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs (Read).


Corporate Responsibility

Maxwell believes in the power of humans to transform fear into hope. Perseverance runs in our DNA. It is only when faced with our darkest fears that we become our most brilliant.


Maxwell offers an equal opportunity to people of all races, genders and identities – the opportunity to strive, to fail, to hope, to persevere, to overcome and win. Maxwell looks for people who are hungry to create change, to compassionately and powerfully make a difference in the lives of others.


Maxwell’s team believes they have what it takes to change the world; they collaborate with hard working, intelligent team members to make that change a reality every single day.